Cell therapies
Cell sheets in cell therapies
... of cell suspensions, the use of planar surfaces has enabled simple and effective delivery of cells to different clinical indications [99, 108, 145, 146], demonstrating the versatility of this ...in cell ...
24
Advances in Sickle Cell Therapies in the Hydroxyurea Era
... Hematopoietic stem cell transplanta- tion (HSCT) offers the potential for a cure from SCD. Largely as an extension of the thalassemia experience, HSCT has been investigated in patients with SCD for the past 30 ...
6
Chimeric antigen receptor T cell therapies for multiple myeloma
... B cell malignancies such as acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) ...CAR-T cell therapy (CTL019) infusion led to a durable complete response in an advanced refractory MM ...
12
Enabling stem cell therapies through synthetic stem cell–niche engineering
... Strategies to engineer a stem cell niche. There are a variety of approaches to engineer and control individual niche components. These strategies can be multiplexed to produce hybrid devices that simultaneously ...
12
Orthopaedic applications of nanoparticle-based stem cell therapies
... limited therapies or ...these therapies from research to the ...to cell surface ...of cell localisation and associated tissue regeneration can therefore be enhanced, particularly for in vivo ...
12
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
... Stromal cell-derived factor 1; Ang-1: Angiopoietin-1; BCL-2: B cell lymphoma 2; IGF-I: Insulin-like growth factor-I; STC-1: Stanniocalcin-1; TGF- β : Transforming growth factor β ; GM- CSF: Granulocyte – ...
16
Cell therapies for pancreatic beta-cell replenishment
... Pancreatic ducts, exocrine pancreas and islet of Langerhans are proposed as sources of pancreatic stem/progenitor cells. Although their nature and even their existence were ini- tially subject of controversy in the field ...
9
Clinical trials for stem cell therapies
... timing, cell type and dose, and delivery ...stem cell secretions or cytokines released at the site of injury and the degree of cardio-repair that may be clinically relevant ...than cell-based ...
7
Stem cells and cell therapy: From basic sciences to clinical perspectives
... On the basis of these studies, a Phase 1 investigation involving patients with chronic idiopathic cardiomyopathy resulting from chagasic cardiopathy was started. Mono- nuclear cells were aspirated from various sites of ...
10
The advancement of human pluripotent stem cell derived therapies into the clinic
... cardiac contractility, and hPSC-derived cell therapies offer two possible mechanisms of action to achieve this. First, cardiomyocytes derived from hPSCs could integrate into the host myocardium and directly ...
9
A biomaterials approach to influence stem cell fate in injectable cell based therapies
... MSC-based cell therapies, an understanding of the fac- tors that influence the functionality of cells post injec- tion is ...as cell transplantation vehicles, saline-based cell carriers still ...
15
The pluralization of the international : resistance and alter standardization in regenerative stem cell medicine
... stem cell applications is intimately linked to high economic and therapeutic hopes (McMahon, ...stem cell therapies (especially the Japanese-invented iPS cells), which aims to aid in the translation ...
29
Stem cell delivery of therapies for brain disorders
... The influence of exosomes on the stem cell microenviron- ment and ensuing cellular function has also been studied within the context of miRNA. The exosome-containing miRNAs can modulate functional changes when ...
10
Paradox of B cell–targeted therapies
... tion, whereas B cells are required for the expansion of autoantigen-specific T cells during disease progression. Given the existence of such regulatory B cells in humans, these findings not only resolve previously ...
5
Conventional and novel stem cell based therapies for androgenic alopecia
... 55. Chen CH, Hung HS, Hsu SH. Low-energy laser irradiation increases endothelial cell proliferation, migration, and eNOS gene expression possibly via PI3K signal pathway. Lasers Surg Med. 2008;40(1):46–54. 56. ...
9
B cell targeted therapies
... Therapies that inhibit BLyS currently under development include soluble receptors such as TACI-Ig and anti-BLyS monoclonal antibodies. Furie and coworkers [3] conducted a phase I investigation of belimumab ...
6
Basal cell carcinoma — molecular biology and potential new therapies
... Basal cell carcinoma (BCC) of the skin, the most common malignancy in individuals of mixed European descent, is increasing in incidence due to an aging population and sun exposure ...tumor cell of origin, ...
10
Hairy cell leukemia – immunotargets and therapies
... Hairy cell leukemia (HCL) is an indolent low-grade B-cell lymphoproliferative disorder that is reasonably sensitive to standard first-line purine analog ...and therapies that may provide deeper ...
14
Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies
... of cell-free DNA in accessible body fluids (blood and urine) could provide a measure both for the disease burden and for therapeutic success, but this needs a careful proof in a prospective ...
11
The current status of immunobased therapies for metastatic renal-cell carcinoma
... Cellular death is caused by both direct and indirect methods (Figure 2). The intracellular component has higher osmolarity and freezes more slowly than the extracellular component; as a result, fluid shifts out of the ...
11